Clinical Trials Logo

Pharmacogenetic Testing clinical trials

View clinical trials related to Pharmacogenetic Testing.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04630093 Completed - Clinical trials for Pharmacogenetic Testing

Pilot of Preemptive Pharmacogenetics in Medically Underserved Patients

Start date: May 13, 2021
Phase: N/A
Study type: Interventional

This is a pragmatic clinical trial of 100 patients who self-identify as black or Latino. Patients with active prescriptions for at least 3 medications and a medication change within the past 6-months will be recruited from the University of Florida (UF) Health primary care clinics for panel-based pharmacogenetic testing. Participants will be followed for 6 months and will undergo assessments with the Treatment Satisfaction Questionnaire for Medication (TSQM) three times (baseline visit, 3-month visit, and 6-month visit post pharmacogenetic testing). In addition, data on effectiveness outcomes and socioeconomic measures will be collected via the electronic health record (EHR) and patient report. Participation is expected to last approximately 6 months and the study will be open for approximately 12-14 months.

NCT ID: NCT03468309 Completed - Clinical trials for Pharmacogenetic Testing

Medication Optimization Using Pharmacogenetic Testing and the G-DIG to Reduce Polypharmacy in a Mental Health Population

MedOPT
Start date: January 1, 2018
Phase:
Study type: Observational

Use of polypharmacy has significantly increased over the past two decades, which has unproven clinical benefit and is associate with an increased the risk of adverse side effects. Pharmacogenetic assays, such as the Genecept® Assay, have the purported benefit of being able to predict response(s) to specific medication based on genetic markers. Thus, this study is a 12-week open-label, naturalistic study of the provision of pharmacogenetic testing and a computerized decision tool for providers to determine the potential efficacy of the assay to reduce polypharmacy and improve patient outcomes.

NCT ID: NCT01600846 Completed - Clinical trials for Pharmacogenetic Testing

Pharmacogenetic Testing in Primary Care

Start date: December 2012
Phase: N/A
Study type: Observational

The purpose of this study is to further integrate pharmacogenetic (PGx) testing into clinical practice by educating physicians about pharmacogenetics and offering testing to their patients. Pharmacogenetic testing may help physicians choose the best drug and dosage for their patients which can reduce side effects, increase effectiveness, and improve patient adherence. Two clinics will be involved. One clinic will have a pharmacist on-site as a resource to physicians and to advise what patients may benefit from PGx testing; the other clinic will have a pharmacist on call. Patient and physician perspectives about PGx testing and their utilization will be examined via surveys. The investigators hypothesize that with education about PGx testing, more physicians will utilize testing.